36th week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090220939 | Methods for determing resistance or susceptibility to hi entry inhibitors - The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV. | 2009-09-03 |
20090220940 | Method for Testing the Integrity of Membranes - A method for evaluating the integrity of microfiltration, ultrafiltration and nanofiltration membranes, which method comprises passing a liquid that contains a substantially mono-dispersed population of nano-probes through said membrane to form a permeate and testing said permeate for the presence of said nano-probes, wherein the non-detection of said nano-probes in said permeate indicates that said membrane is substantially intact. | 2009-09-03 |
20090220941 | COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND KITS AND METHODS USING SAME - An isolated composition-of-matter comprising a sialic acid bound to a sialic acid binding domain of a polypeptide is provided. Uses thereof and kits comprising same are also provided. | 2009-09-03 |
20090220942 | ACTIVATED SPLIT-POLYPEPTIDES AND METHODS FOR THEIR PRODUCTION AND USE - The present invention relates to a method to produce activated split-polypeptide fragments that on reconstitution immediately forms an active protein. The method relate to real-time protein complementation. Also encompassed in the invention is a method to split and produce split-fluorescent proteins in an active state which produce a fluorescent signal immediately on reconstitution. The present application also provides methods to detect nucleic acids; non-nucleic acid analytes and nucleic acid hybridization in real-time using the novel activated split-polypeptide fragments of the invention. | 2009-09-03 |
20090220943 | HCV GENOTYPING AND PHENOTYPING - The present invention includes methods of genotyping and phenotyping HCV. In one embodiment, the methods of the invention can be used to determine whether a HCV isolate is resistant to an antiviral drug. The invention also includes primers for amplifying a HCV NS3 region and kits. | 2009-09-03 |
20090220944 | Method to measure and characterize microvesicles in the human body fluids - This disclosure provides a method to capture, detect, characterize and quantify human exosomes in small volumes of human body fluids by using a sandwich ELISA test. This method allows a full characterization of an exosome preparation, thus providing a tool to distinguish a disease-related condition from a healthy state, by the use of a non-invasive assay. In fact, this method may be useful in screening, diagnosis and prognosis of tumors, with a simple plasma sample. At the same time measurement of circulating exosomes may provide information on the level of tumor mass present in a patient. The method provided here is suitable to evaluate presence of some infectious and/or transmissible agents, such as viral proteins or prion proteins, within circulating exosomes. | 2009-09-03 |
20090220945 | HPV E6, E7 mRNA ASSAY AND METHODS OF USE THEREOF - Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology. | 2009-09-03 |
20090220946 | ADENOVIRUS STATUS AS A PREDICTOR OF BODY COMPOSITION CHANGE, DISEASE STATUS, AND TREATMENT OUTCOMES - Infection with obesifying adenoviruses in animals and humans may be used to predict changes in body weight and disease status. More particularly, infection with certain adenoviruses, such as adenovirus type 36 (Ad-36) and adenovirus type 37 (Ad-37) may cause removal of the normal equilibrium factors that control fat cell metabolism and may make individuals more responsive than normal individuals to perturbations, which cause body composition change including weight gain or weight loss. | 2009-09-03 |
20090220947 | Biomarkers for toxic algae - The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can serve as biomarkers. | 2009-09-03 |
20090220948 | Methods and Device for Transmitting, Enclosing and Analysing Fluid Samples - A microfluidic device for analysing a fluid sample comprises at least one sample transmission channel; at least one multi-functional channel; and at least one reactor module which provides a fluid connection between the sample transmission channel and the multi-functional channel. Each reactor module comprises at least one reaction chamber, having at least one inlet in fluid communication with the sample transmission channel(s); and at least one fluid isolation chamber, which is in fluid communication with the outlet(s) of the reaction chamber(s). The fluid isolation chamber serves to isolate the fluid sample from the multi-functional channel(s). | 2009-09-03 |
20090220949 | Mutations Associated with the Long QT Syndrome and Diagnostic Use Thereof - The present invention is based on the identification of new mutations in KCNQ1 (also termed KvLQTI), KCNH2 (also termed HERG), SCN5A, KCNE1 (also termed minK), KCNE2 (also termed MiRP) genes that encode ionic channels involved in cardiac electrical activity and are potentially responsible for the Long QT Syndrome. According to a main aspect, the invention relates to nucleic acids, oligonucleotides and polynucleotides and mRNA, containing sequences of KCNQ1, KCNH2 SCN5A, KCNE1, KCNE2 genes and cDNAs in a mutated form and to respective variant proteins thereof. A preferred embodiment of the present invention is represented by a diagnostic method based on the identification of a group of about 70 non-private mutations in the KCNQ1, KCNH2 and SCN5A genes, detected at high frequency. The method, which is able to identify about 40% of the probands, is non exclusively based on identification of mutations that are described and characterized in this invention where said identification has both prognostic and diagnostic value for the Long QT Syndrome. | 2009-09-03 |
20090220950 | SIMULTANEOUS QUANTIFICATION OF NUCLEIC ACIDS IN DISEASED CELLS - Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents. | 2009-09-03 |
20090220951 | Methods and compositions for classifying bacillus bacteria - A method of classifying a | 2009-09-03 |
20090220952 | Compositions And Methods For Analyzing Protein Interactions - The present invention relates to compositions and methods for analyzing and modulating (e.g., enhancing or inhibiting) protein-protein interactions. In particular, compositions and methods of the present invention find use in identifying, reconstituting and characterizing protein-protein interactions, identifying binding subunits, and drug screening. The methods and compositions of the invention may also be used to identify agents that may agonize or antagonize a protein-protein interaction (e.g., using test compounds). | 2009-09-03 |
20090220953 | IDENTIFICATION OF ANCESTRAL HAPLOTYPES AND USES THEREOF - The present invention relates to the identification of haplospecific geometric elements (HGEs) in a multigene cluster comprising genes encoding complement control proteins. The present invention also relates to methods of performing genomic matching techniques (GMT) which enables the identification of HGEs of a duplicated region within a haplotype block. HGEs identified using the methods of the invention can also be analysed to determine if they are markers for a trait of interest such as a disease trait. Furthermore, the present invention relates to methods of determining an individual's susceptibility or predisposition to age-related macular degeneration, recurrent spontaneous abortion, Sjögren's Syndrome and/or psoriasis vulgaris by analysing the genotype of the individual within a multigene cluster comprising genes encoding complement control proteins. | 2009-09-03 |
20090220954 | METHODS OF DIAGNOSING CARDIOVASCULAR DISEASE - Methods are disclosed for diagnosing increased risk of cardiovascular disease in a subject. | 2009-09-03 |
20090220955 | METHODS AND COMPOSITION TO GENERATE UNIQUE SEQUENCE DNA PROBES LABELING OF DNA PROBES AND THE USE OF THESE PROBES - The invention relates generally to the field of identification of DNA sequences, genes or chromosomes. Methods and composition to obtain Unique Sequence DNA probes are provided. Composition comprises of any double stranded DNA containing Unique Sequences from which the repetitive sequences are eliminated according to the method described in this invention. The invention also relates to the preservation of cells that have been identified after immunuomagnetic selection and fluorescent labeling in order to further interrogate the cells of interest. Furthermore the invention relates to genetic analysis of cells that have been identified after immunomagnetic selection and fluorescent labeling. | 2009-09-03 |
20090220956 | Prediction of Local Recurrence of Breast Cancer - The invention relates to the field of medicine, in particular to cancer, more specifically breast cancer, most specifically to a method to predict the local recurrence of breast cancer after breast conserving therapy. It has been demonstrated that a classification on basis of the similarity of the gene expression profile to the gene expression profile of (serum) activated fibroblasts is able to distinguish significantly in risk of local recurrence in breast cancer patients. | 2009-09-03 |
20090220957 | MEMBRANE ASSAY METHOD - The present invention provides an assay method for a cell-containing body sample, said method comprising treating said sample under conditions whereby to cause cell lysis, preferably by means of a detergent; and subjecting the thus-generated lysed sample to conditions causing the cleavage of nucleic acid molecules. The invention additionally provides the use of nucleic acid cleavage conditions in enhancing a membrane assay, a device for carrying out such an assay, and a kit for use in the assay. | 2009-09-03 |
20090220958 | METHOD FOR DIAGNOSING HEPATIC DISEASES AND SCREENING METHOD OF MOLECULES FOR TREATMENT OF HEPATIC DISEASE - The invention relates to a method for diagnosticating hepatic diseases consisting in measuring an apolipoprotein A4 expression in hepatic cells or tissues and in the circulation (blood, plasma, serum. A method for screening molecules for treating said diseases by bringing into contact said compounds with a mammal and for measuring the apolipoprotein A4 expression in said hepatic origin cells or in the circulation of said mammal is also disclosed. | 2009-09-03 |
20090220959 | MARKERS OF DEFINITIVE ENDODERM - Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed. | 2009-09-03 |
20090220960 | LUCIFERASE GENE OPTIMIZED FOR USE IN IMAGING OF INTRACELLULAR LUMINESCENCE - The present invention provides a gene construct encoding pH insensitive luciferase for visualizing intracellular information, wherein an intracellular expression activity is higher compared with a gene construct of luciferase derived from a firefly. | 2009-09-03 |
20090220961 | Fluorescent Primer System For Detection Of Nucleic Acids (Q Priming) - The present invention is directed to a self-quenching primer comprising; a fluorophore that can be quenched by guanine; an oligonucleotide sequence that forms a hairpin; an oligonucleotide that is a target specific sequence and; use in amplification reactions, particularly in polymerase chain reactions, during which the fluorophore is released thereby emitting fluorescence. | 2009-09-03 |
20090220962 | MICROGININ PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AS WELL AS METHODS FOR CREATING NOVEL MICROGININS - The invention provides for nucleic acid molecules enabling the synthesis of microginin and microginin analogues. The invention also provides for methods for identifying microginins as well creating microginins which may not be found in nature. | 2009-09-03 |
20090220963 | KIT SUITABLE FOR SCREENING AND ESTABLISMENT OF OPTIMAL AMPLIFICATION CONDITION IN PCR CONSTRUCTED WITH DRIED-FORMULATED PCR REAGENT AND METHOD FOR PRODUCING THE SAME - The present invention relates to a kit for screening and establishing optimal amplification condition for individual PCR using a dried-formulated PCR reagent which is composed of different combinations of various components affecting PCR result, to provide a method for screening and establishment of optimal amplification in PCR constructed with a dried-formulated PCR reagent. According to the present invention, researchers can perform PCR under the optimal amplification conditions appropriate for individual PCR even with a PCR-related product constructed from a dried-formulated PCR reagent, suggesting that a unique target gene can be efficiently amplified by PCR constructed with a dried-formulated PCR reagent under the more appropriate conditions. | 2009-09-03 |
20090220964 | METHODS FOR DIAGNOSING AND TREATING CANCERS VIA MANIPULATIONS OF A...PATHWAY - Methods for diagnosing, treating, and screening for cancer based on manipulations of a newly discovered pVHL dependent, non-degradative ubiquitylation pathway of Rpb1. In particular, methods comprising the use of biomarkers implicating the pathway, and promoters of either or both of P1465 hydroxylation and CTD Ser-5 phosphorylation of Rpb1. Specifically, the methods may be used to inhibit tumor growth, including, in particular, carcinomas such as renal clear cell carcinoma. | 2009-09-03 |
20090220965 | METHODS FOR PROGNOSING THE RECURRENCE OF GASTROINTESTINAL AND OTHER CANCERS USING THE SHC PROTEINS - The invention relates to methods for prognosing the recurrence of gastrointestinal and other cancers using tyrosine phosphorylated Shc (PY-Shc) and/or p66-Shc. | 2009-09-03 |
20090220966 | THERMOCYCLER AND SAMPLE PORT - The invention relates to continuous flow systems, in particular thermocyclers for the automated and continuous cycling of fluid between a plurality of temperature zones in the amplification of nucleic acids. The invention also relates to an improved sample port for introducing a volume of a liquid sample into a continuous flow system. | 2009-09-03 |
20090220967 | Systemic Carnitine Deficiency Gene and Uses Thereof - The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein. | 2009-09-03 |
20090220968 | Methods and Apparatus for Near Field Irradiation - Irradiation methods and apparatus configured to deliver power, via electromagnetic fields at a variety of frequencies and power levels, in a localized fashion to a target area. In one example, an electromagnetic field generator is disposed on a substrate and configured to deliver power via electromagnetic energy to a thin region proximate to (above) a surface of the substrate, wherein electromagnetic field intensity decreases significantly beyond the thin region. Such methods and apparatus are particularly useful in a wide variety of processes involving chemical and/or physical interactions in connection with a sample of interest located in the thin region. In different aspects, irradiator apparatus may be configured as disposable devices, and/or used in combination with one or more microfluidic or sensing components, for a variety of medical/laboratory/diagnostic methods and instrumentation implementations. | 2009-09-03 |
20090220969 | Identifying and quantifying small RNAs - One-step RT-PCR methods, compositions and kits for the detection and quantification of small RNAs in a sample are disclosed. The one-step RT-PCR approach involves polyadenylation of a small RNA followed by reverse transcription with a first primer containing a poly(T) sequence and at least two 3′ nucleotides complementary to the 3′ terminal end nucleotides of the small RNA, to produce a cDNA. This may be followed by PCR amplification using the same first primer as the revere primer and a second, forward primer in which a portion of its sequence is complementary to the 3′ terminal end of the cDNA. This may be then followed by detection and/or quantification of the amplified product. | 2009-09-03 |
20090220970 | MOLECULAR TOXICOLOGY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 2009-09-03 |
20090220971 | Treatment Response in Generalized Social Phobia - This invention generally pertains to the field of psychiatry. In particular, this invention relates to, inter alia, the discovery that a subject's serotonin transporter gene promoter polymorphism genotype can be used to determine the subject's response to certain drug therapies. | 2009-09-03 |
20090220972 | Probe, Probe Set, Probe-Immobilized Carrier, and Genetic Testing Method - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 49 to 51 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 2009-09-03 |
20090220973 | OBESITY AND BODY FAT DISTRIBUTION - Described are methods for predicting and diagnosing genetically-based obesity and body fat distribution, and for identifying compounds for the treatment and prevention of obesity. | 2009-09-03 |
20090220974 | METHODS AND APPARATUS FOR THE SELECTION AND/OR PROCESSING OF PARTICLES, IN PARTICULAR FOR THE SELECTIVE AND/OR OPTIMISED LYSIS OF CELLS - Methods and apparatus for the selection or processing of particles sensitive to the application of an external stimulus, in which is produced, by applying the external stimulus, the rupture/lysis of at least one selected particle or the fusion of first and second selected particles, by means of the organisation of the particles using a first field of force by selectively energising electrodes of an array of selectable electrodes having dimensions comparable to or smaller than those of the particles, applying to the electrodes a first configuration of stresses; and by applying to the electrodes a second configuration of stresses, so as to create a second field of force, located substantially close to at least one selected particle to be lysated or to a pair of first and second particles to be fused and such as to produce the application of a stimulus suited to produce their lysis or fusion. | 2009-09-03 |
20090220975 | USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER - The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type. | 2009-09-03 |
20090220976 | Test Method for MALT Lymphomas and Kit Therefor - An object of the present invention is to provide a test method for MALT lymphomas for providing genetic diagnosis data which can be used for the diagnosis of MALT lymphomas, identification of disease type, and prediction of progression of pathological conditions and onset thereof and a kit for implementing the method. At least two types of tumor-suppressor genes or cancer-related genes are selected, in particular, at least two types of genes are selected from a gene group consisting of 11 genes in a sample, and the expression levels or the gene expression regulation status of the selected genes are investigated. Early detection and diagnosis with high sensitivity and accuracy can be conducted by quantitatively determining the genetic product and preparing the expression profiles of the gene group on the basis of the results, or by detecting methylation frequencies to analyze the expression regulation. | 2009-09-03 |
20090220977 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 2009-09-03 |
20090220978 | METHODS FOR DETECTION AND QUANTIFICATION OF ANALYTES IN COMPLEX MIXTURES - The invention provides a diverse population of uniquely labeled probes, containing about thirty or more target specific nucleic acid probes each attached to a unique label bound to a nucleic acid. Also provided is a method of producing a population of uniquely labeled nucleic acid probes. The method consists of (a) synthesizing a population of target specific nucleic acid probes each having a different specifier; (b) synthesizing a corresponding population of anti-genedigits each having a unique label, the population having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) hybridizing the populations of target nucleic acid probes to the anti-genedigits, to produce a population in which each of the target specific probes is uniquely labeled. Also provided is a method of detecting a nucleic acid analyte. The method consists of (a) contacting a mixture of nucleic acid analytes under conditions sufficient for hybridization with a plurality of target specific nucleic acid probes each having a different specifier; (b) contacting the mixture under conditions sufficient for hybridization with a corresponding plurality of anti-genedigits each having a unique label, the plurality of anti-genedigits having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) uniquely detecting a hybridized complex between one or more analytes in the mixture, a target specific probe, and an anti-genedigit. | 2009-09-03 |
20090220979 | Methods and Apparatus for Magnetic Separation of Cells - Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput. | 2009-09-03 |
20090220980 | USE OF METHYLATION STATUS OF MINT LOCI AND TUMOR-RELATED GENES AS A MARKER FOR MELANOMA AND BREAST CANCER - The invention relates to a method of detecting melanoma or breast cancer using DNA methylation in MINT17, MINT31, or the promoter region of WIF1, TFPI2, RASSF1A, SOCS1, GATA4, or RARβ2 as a biomarker. Also disclosed are methods of using the biomarker for determining the cancer status and predicting the outcome of the cancer. | 2009-09-03 |
20090220981 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF CHLAMYDOPHILA PNEUMONIAE IN A TEST SAMPLE - Oligonucleotides for use in determining the presence of | 2009-09-03 |
20090220982 | COMPOSITIONS AND METHODS FOR DETERMINING NEPHROTOXICITY - The present invention provides novel in vitro assays for determining the nephrotoxicity of a compound. These assays correlate well with in vivo nephrotoxicity and also provide high-throughput methods to screen multiple compounds for in vivo nephrotoxicity. In addition, the methods of the present invention may be adapted to screen for nephroprotectant compounds, including those that protect cells and animals from the nephrotoxic effects of aminoglycoside antibiotics. | 2009-09-03 |
20090220983 | CELL-BASED METHODS FOR DETECTING AND/OR MEASURING BMP-12-RELATED PROTEIN ACTIVITY - The invention provides cell-based methods to detect and/or measure the BMP-12-related protein activity of a sample containing a BMP-12-related protein. The methods involve contacting a suitable cell with the sample, and measuring the expression level of at least one BMP-12-related-activity-marker. A dose-dependent increase(s) in the level(s) of the BMP-12-related-activity-markers is indicative of the BMP-12-related protein activity in the sample. The levels of the BMP-12-related-activity-markers of the invention exhibit a dose-responsive increase in response to known BMP-12-related proteins BMP-12, BMP-13, and MP-52, but not to the osteogenic protein, BMP-2. | 2009-09-03 |
20090220984 | HEAT FLOW POLYMERASE CHAIN REACTION SYSTEMS AND METHODS - Methods and systems for polymerase chain reactions (PCR) that are capable of detecting amplified DNA during or after the PCR process. The methods and systems may utilize DSC or DTA analysis techniques. | 2009-09-03 |
20090220985 | RAPID EFFICACY ASSESSMENT METHOD FOR LUNG CANCER THERAPY - The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using qPCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on qPCR results to correlate the amount of circulating cancer cells in lung cancer patients and predict the treatment outcomes. | 2009-09-03 |
20090220986 | ASSESSING NON-ALCOHOLIC FATTY LIVER DISEASE - The document provides methods and materials related to assessing NAFLD in a mammal. For example, methods and materials for determining whether or not a mammal has an NAFLD are provided. In addition, methods and materials for determining whether a mammal with an NAFLD has a severe or mild form of the NAFLD as well as methods and materials for determining whether a mammal with an NAFLD is likely to experience a severe or mild form of the NAFLD are provided. | 2009-09-03 |
20090220987 | Use of Intramolecularly, Covalently Cross-Linked Proteins As Binding Partners In Immunoassays - The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase. | 2009-09-03 |
20090220988 | METHOD OF REVEALING A BIOLOGICAL PROCESS USING A FRET MEASUREMENT - The present invention relates to a method of revealing a biological process using a FRET measurement, which comprises the following steps:
| 2009-09-03 |
20090220989 | Particle-Based Analyte Characterization - Methods for assaying a sample for an analyte are provided. In various embodiments, the methods comprise contacting a sample suspected of containing the analyte with a non-uniform particle comprising a capture molecule, and further contacting the particle with a detection moiety comprising a label that permits detection of the analyte when associated with the particle. The methods may be performed to detect and/or quantitate analyte in the sample. In some embodiments, the methods may be performed in an automated manner, and may use an optical and/or cytometric apparatus for performing the method(s). The methods may further be performed with automated vessel-processing apparatus(es), such as plate loaders, plate washers, etc. Also provided are complexes containing the described materials formed by an assay of the invention, including excited state complexes. Kits useful for performing such methods are also provided. | 2009-09-03 |
20090220990 | METHOD AND KIT FOR DETECTING CONDITION IN PATIENT WITH DISTURBANCE OF CONSCIOUSNESS - A method for detecting a condition in a patient with disturbance of consciousness, by analyzing an amount and/or activity of a von Willebrand factor-cleaving protease, and a kit for detecting a condition in a patient with disturbance of consciousness, comprising an antibody or a fragment thereof which specifically binds to a von Willebrand factor-cleaving protease, or a von Willebrand factor or a fragment thereof, are disclosed. Examples of the detection of a condition include a detection of cerebrovascular disease, a detection of arteriosclerotic vascular disease, and a detection or prediction of severity. | 2009-09-03 |
20090220991 | Reagents for the detection of protein phosphorylation in leukemia signaling pathways - The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins. | 2009-09-03 |
20090220992 | METHODS FOR THE IDENTIFICATION OF LRRK2 INTERACTING MOLECULES AND FOR THE PURIFICATION OF LRRK2 - The invention provides in a first aspect a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, incubating the indol ligand 91-LRRK2 complex with a given compound, and determining whether the compound is able to separate LRRK2 from the immobilized indol ligand 91. Furthermore, the invention relates to a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and detecting the indol ligand 91-LRRK2 complex. Additionally, the invention provides a method for the identification of an LRRK2 interacting compound, comprising the steps of providing two aliquots of a protein preparation containing LRRK2, contacting one aliquot with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, contacting the other aliquot with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and determining the amount of indol ligand 91-LRRK2 complex. Furthermore, the invention relates to a method for the purification of LRRK2, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and separating LRRK2 from the immobilized indol ligand 91. | 2009-09-03 |
20090220993 | Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules - The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition. | 2009-09-03 |
20090220994 | METHODS FOR DIAGNOSIS OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME - The present invention relates to methods for diagnosis of chronic prostatitis/chronic pain pelvic syndrome (CP/CPPS). We have found specific biomarkers that are present in higher concentrations in patients that have chronic prostatitis/chronic pain pelvic syndrome (CP/CPPS) as compared to subjects that have no symptoms of CP/CPPS. In particular, uromodulin (THP), aminopeptidase N (AMPN), dipeptidylpeptidase IV (CD26), neprilysin (NEP), zinc-α-2-glycoprotein (ZA2G) and alkaline phosphatase (ALP) were found to be present at higher concentrations in CP/CPPS patient urine that is voided after prostatic message. Accordingly, the invention is directed to methods for diagnosis of CP/CPPS by monitoring the levels of at least one of these proteins in post-prostatic massage urine, as well as to diagnostic kits designed for diagnosis of CP/CPPS. | 2009-09-03 |
20090220995 | MULTIPLE ADMINISTRATIONS OF UMBILICUS DERIVED CELLS - A method to determine the optimal administration protocol of allogeneic donor tissue to treat a disease in a human, using an animal model of human disease. | 2009-09-03 |
20090220996 | In vitro Assay Methods for Classifying Embryotoxicity of Compounds - The present disclosure provides methods useful for screening compounds and/or compositions, for example potential drug candidates. The results of the screening assays correlate to the effects of the compounds on the molecular and/or cellular level of the human body. Also disclosed are screening assays utilizing human embryonic stem cells RELICELL®hES of Indian origin. The methods disclosed herein correlate well with animal preclinical toxicity studies done in a clinical trial setup. | 2009-09-03 |
20090220997 | Stimulating G Protein-Coupled Receptors - This document provides methods and materials related to activating GPCRs. For example, methods and materials for activating GPCRs present on cells (e.g., human cell) as well as methods and materials for identifying GPCR agonists are provided. | 2009-09-03 |
20090220998 | Platelet Aggregation Assays - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 2009-09-03 |
20090220999 | Antibodies immunoreactive with mutant 5-enolpyruvlshikimate-3-phosphate synthase - Antibodies immunoreactive to double mutant EPSPS are provided, and in an embodiment the double mutant EPSPS is one in which the wild-type EPSPS is substituted at residue 102 with isoleucine and at residue 106 with serine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies. | 2009-09-03 |
20090221000 | METHODS OF QUANTIFYING TASTE OF COMPOUNDS FOR FOOD OR BEVERAGES - Methods of quantifying the taste of compounds for food and beverages are provided. These methods comprise contacting the compounds with an isolated heteromeric receptor comprising at least one T1R2 polypeptide and at least one T1R3 polypeptide. | 2009-09-03 |
20090221001 | Methods for identifying compounds that modulate the T1R1/T1R3 umami taste receptor - Methods for identifying compounds that modulate the T1R1/T1R3 umami taste receptors are provided. These methods comprise screening for compounds that compete with lactisole for binding to and/or inhibiting the T1R1/T1R3 umami taste receptor. | 2009-09-03 |
20090221002 | Methods of quantifying taste of compounds for food or beverages - Methods of quantifying the taste of compounds for food and beverages are provided. These methods comprise contacting the compounds with an isolated heteromeric receptor comprising at least one T1R1 polypeptide and at least one T1R3 polypeptide. | 2009-09-03 |
20090221003 | PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY - The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines. | 2009-09-03 |
20090221004 | Caspase-cleavage anti-keratin antibodies for detection of apoptosis - The present invention relates to the field of detecting and quantifying apoptosis. In one aspect, the invention is directed to an isolated monoclonal or polyclonal antibody that specifically recognizes caspase-generated products of K18 or K19 but does not react with intact K18 or K19. The antibody typically reacts with the cleavage site of K18 or K19 at Asp237. The binds to the epitope common to caspase-cleaved K18 and K19-(T/S)VEVD- and the Asp-proximal valine is essential for antibody recognition. | 2009-09-03 |
20090221005 | METHOD FOR DETECTING ANTIGEN SPECIFIC OR MITOGEN-ACTIVATED T CELLS - The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/or CD8+ T cells is also disclosed. | 2009-09-03 |
20090221006 | DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease. | 2009-09-03 |
20090221007 | DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease. | 2009-09-03 |
20090221008 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 2009-09-03 |
20090221009 | Diagnostic Method for Disorders Using Copeptin - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases. | 2009-09-03 |
20090221010 | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors. | 2009-09-03 |
20090221011 | Coagulation test system - A test element for the determination of coagulation in a plasma or whole blood sample having a first surface ( | 2009-09-03 |
20090221012 | Method for Detecting Procoagulant Phospholipid - The present invention relates to a method for determining the amount of procoagulant phospholipid in a sample, said method comprising steps (i) to (iii) performed in the following order: (i) forming an admixture of the sample and a substrate plasma which has been rendered free or substantially free of procoagulant phospholipid sufficient to at least reduce the capacity of the substrate plasma to coagulate, wherein said substrate plasma has been rendered free or substantially free of procoagulant phospholipid by treatment with a phospholipase; (ii) contacting the admixture with a reagent for activating coagulation of plasma in conditions were procoagulant phospholipids is the rate limiting component of the mixture; and (iii) determining the clotting time if the admixture. | 2009-09-03 |
20090221013 | METHOD FOR QUANTIFYING LIVING COLIFORM MICROORGANISMS IN A WATER SAMPLE - The invention relates to a method of rapidly quantifying living coliform microorganisms in a sample of water in which the microorganisms are put into contact with a fluorogenic substrate that is hydrolyzed in methylumbelliferone by an enzyme given off by the microorganisms. Methylumbelliferone is detected by the fluorescence that it emits, with the rate at which this fluorescence varies being measured in order to determine the concentration of coliform microorganisms in the original sample on the basis of the calculated rate of variation and a correlation plot. In characteristic manner, a preliminary treatment step is performed on the sample, in particular pre-filtering, serving to remove at least some of the particles in suspension in the water, thus making it possible to achieve quantification that is entirely comparable with the quantification given by the standardized multi-well panel method. The invention is applicable to analyzing bathing water for detecting | 2009-09-03 |
20090221014 | Enzymatic Biosensors With Enhanced Activity Retention For Detection Of Organic Compounds - Enzymatic biosensors and methods of producing distal tips for biosensor transducers for use in detecting one or more analytes selected from organic compounds susceptible to dehalogenation, organic compounds susceptible to oxygenation, organic compounds susceptible to deamination, organosulfate compounds susceptible to hydrolysis, and organophosphate compounds susceptible to hydrolysis are disclosed herein, as well as biosensor arrays, methods of detecting and quantifying analytes within a mixture, and devices and methods for delivering reagents to enzymes disposed within the distal tip of a biosensor. | 2009-09-03 |
20090221015 | Detecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling - Disclosed herein are methods of detecting and predicting diastolic heart failure and predicting congestive heart failure comprise protease and protease inhibitor profiling. | 2009-09-03 |
20090221016 | MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF - The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE. | 2009-09-03 |
20090221017 | ANTI-AMYLOID BETA ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN VITRO - The present invention relates to a cell-based in vitro screening assay for identifying and selecting therapeutic agents that inhibit amyloid r-induced cytotoxicity. | 2009-09-03 |
20090221018 | Procine circovirus type 2 vaccines - The present invention is based on the ORF3 gene of Porcine Circovirus Type 2 (PCV2) and the identification of tis apoptotic role. This discovery has led to the development of an attenuated live vaccine against PCV2. | 2009-09-03 |
20090221019 | Core-Modified Terpene Trilactones From Ginkgo Biloba Extract and Biological Evaluation Thereof - Lactone-rings of ginkgolides are converted into the corresponding tetrahydrofuran moieties via DIBAL-H reduction followed by deoxygenation of the formed lactols with Et | 2009-09-03 |
20090221020 | Mass Spectrometry Assays for Acetyltransferase/Deacetylase Activity - Provided are methods for determining the activity of proteins that modulate the acetylation state of a protein substrate. The methods may be used for determining both acetyltransferase activity and deacetylase activity. The methods utilize mass spectrometry for determining the acetylation state of a substrate peptide. The methods may also be used to identify compounds that modulate the activity of a protein having acetyltransferase or deacetylase activity. | 2009-09-03 |
20090221021 | DISTINCTION BETWEEN BACTERIAL MENINGITIS AND VIRAL MENINGITIS - The present invention relates to the field of the distinction between bacterial meningitis and viral meningitis. It relates in particular to an in vitro method for detecting the presence of bacterial meningitis, which comprises determining the concentration of procalcitonin present in a test blood sample and of proteins present in a test cerebrospinal fluid sample, and comparing the concentrations thus determined to the concentration of procalcitonin and of proteins present in a reference sample or to a reference value. It also relates to a kit comprising means for detecting procalcitonin and proteins in the cerebrospinal fluid, and to the use thereof for the production of a diagnostic tool for bacterial meningitis. | 2009-09-03 |
20090221022 | Three Dimensional Cell Culture - A method for culturing preadipocytes isolated ex vivo is described, the method including introducing preadipocytes into a three dimensional support matrix, and allowing the cells to differentiate in vitro into adipocytes within the support matrix. The matrix may be a collagen matrix. The method may be used for investigating the development of stem cells, or for investigating the response of adipocytes to stimuli. The method provides a system whereby adipocytes with biological properties resembling those in vivo can be grown in vitro. | 2009-09-03 |
20090221023 | CELL TRAY - A cell tray has a multi-dimensional array of cells in precise, equally spaced wells (cubicles or silos) containing medium of interest. The ordered cell array enables automated processing as well as simultaneous monitoring and analyzing of a large matrix of cells, biological fluids, chemicals and/or solid samples. The invention is an integrated device and is fabricated into substrates similar to microscope slides. The ordered array of cells in precise locations helps in parallel analysis and processing of cells simultaneously. Each cell cubicle or silo in the array is located equidistant from its nearest neighbors in an orthogonal direction. The location of each well can be precisely measured and recorded in an automated processing system. Included in the bottom of each cell well is an optional micro-lens. An array of probes provides parallel cell processing and monitoring capabilities, including microinjection and microscope analysis. | 2009-09-03 |
20090221024 | T CELL ASSAYS - The present invention relates to novel T cell assay methods, in particular where T cell responses to test antigens are increased by removal of regulatory T cells. Novel assays where the timing of incubation with antigens or other samples is varied in order to optimize detection of T cell responses are described. The invention has particular application for measurement of human T cell responses to pharmaceuticals, allergens, irritants or other substances. | 2009-09-03 |
20090221025 | SENSING DEVICE AND METHOD FOR RAPIDLY DETERMINING CONCENTRATIONS OF MICROBIAL ORGANISMS USING INTERFACIAL PHOTO-VOLTAGES - A system for detecting a wide range of microbial organisms, including virus, and determining concentrations in near real-time to determine titer, without the requirement to grow micro-organisms includes an electrometer configured to measure photo-induced interfacial voltages and an electrode assembly with a substrate and at least one electrode on a surface of the substrate electrically coupled to the electrometer. An attachment factor is applied to an exposed surface of each electrode. The attachment factor is effective for interaction with the microbial organism. A transparent vessel for containing the electrolytic solution is provided. The microbial organism may be contained in the electrolytic solution or applied to the coated electrode before being submerged in the electrolytic solution. A light source is configured to controllably produce a flash of activating light directed through the transparent vessel at the electrode causing a sensible photo-induce interfacial voltage indicative of the microbial organism and titer. A corresponding method includes steps of preparing the electrode surfaces with an attachment factor and exposing the submerged electrode surfaces to a flash of activating light to induce interfacial voltages indicative of a determined microbial agent and titer. | 2009-09-03 |
20090221026 | Novel Microorganism And Method For Producing Carotenoid Using The Same - To provide a microorganism capable of producing a large amount of carotenoids, mainly astaxanthin, and to provide a method of producing carotenoids using the microorganism, a microorganism having improved carotenoid productivity is used, which is obtainable by breeding a carotenoid producing | 2009-09-03 |
20090221027 | Use of a bacillus meti gene to improve methionine production in microorganisms - The present invention pertains to improved microorganisms and methods for the production of methionine and other sulfur containing fine chemicals using the metI gene from | 2009-09-03 |
20090221028 | Novel Recombinant Human Hepatitis C Virus-Like Particle and Method for Producing the Same - The present invention relates to a method for producing a recombinant hepatitis C virus-like particle comprising the steps of introducing into (i) a cell in which an RNA replicon comprising a nucleotide sequence comprising the 5′ untranslated region, the nucleotide sequence coding for the NS3, NS4A, NS4B, NS5A, and NS5B proteins, and the 3′ untranslated region of a genome RNA derived from a hepatitis C virus strain autonomously replicates, (ii) a vector expressing the Core, E1, E2, and p7 proteins derived from a hepatitis C virus strain that is the same as or different from that as defined in the above (i), culturing the cell, and recovering the produced virus-like particle, and a recombinant hepatitis C virus particle produced by this method. | 2009-09-03 |
20090221029 | PFU REPLICATION ACCESSORY FACTORS AND METHODS OF USE - This invention provides isolated polynucleotides that encode replication accessory factors. The invention also provides novel DNA replication accessory factors, which have been isolated and purified from the hyperthermophilic archaea | 2009-09-03 |
20090221030 | SIGNAL SEQUENCES AND CO-EXPRESSED CHAPERONES FOR IMPROVING PROTEIN PRODUCTION IN A HOST CELL - The invention provides methods and compositions for improved protein production. The method comprises the steps of: (a) introducing into a host cell a first nucleic acid sequence comprising a signal sequence operably linked to a desired protein sequence; (b) expressing the first nucleic acid sequence; (c) co-expressing a second nucleic acid sequence encoding a chaperone or foldase selected from the group consisting of bip1, ero1, pdi1, tig1, prp1, ppi1, ppi2, prp3, prp4, calnexin, and lhs1; and (d) collecting the desired protein secreted from the host cell. The first nucleic acid sequence optionally comprises an enzyme sequence between the signal sequence and the desired protein sequence. | 2009-09-03 |
20090221031 | NOVEL GROUP OF ESTERASES FOR THE PRODUCTION OF FINE AND SPECIALITY CHEMICALS - The present invention relates to a polynucleotide encoding an enzyme having carboxyl esterase [E.C. 3.1.1.1] activity, wherein the coding sequence is selected from the group consisting of (a) a polynucleotide encoding an amino acid sequence as depicted in any one of SEQ ID NOs: 2, 4, 6 and 8; (b) a polynucleotide having or comprising a nucleotide sequence encoding an enzyme, wherein the nucleic acid sequence is as shown in any one of SEQ ID NOs: 1, 3, 5 and 7; (c) a polynucleotide having or comprising a nucleotide sequence encoding a fragment or derivative of an enzyme encoded by a polynucleotide of (a) or (b), wherein in said derivative one or more amino acid residues are conservatively substituted compared to the amino acid sequence of (a); (d) a polynucleotide encoding an enzyme having carboxyl esterase activity which polynucleotide is at least 65% identical to a polynucleotide encoding an enzyme as shown in one of SEQ ID NOs: 2, 4, 6 and 8; (e) a polynucleotide having or comprising a nucleotide sequence the complementary strand of which hybridizes to a polynucleotide as defined in any one of (a) to (d); and (f) a polynucleotide having or comprising a nucleotide sequence being degenerate to the nucleotide sequence of the polynucleotide of (d) or (e); or the complementary strand of such a polynucleotide of (a) to (f) or fragments thereof useful as specific probes or primers. The present invention also relates to a host, genetically engineered with the polynucleotide of the present invention or the vector of the present invention. The present invention also relates to a polypeptide comprising the amino acid sequence encoded by a polynucleotide of the present invention or which is obtainable by the process of the present invention. Moreover, the present invention relates to a process for producing said polypeptide and for producing bacteria expressing said polypeptide. Finally, the present invention relates to a composition comprising the polynucleotide of the present invention, the vector of the present invention, the host of the present invention, the polypeptide of the present invention, the antibody of the present invention and/or one or more primers of the present invention. | 2009-09-03 |
20090221032 | ENTROPIC BRISTLE DOMAIN SEQUENCES AND THEIR USE IN RECOMBINANT PROTEIN PRODUCTION - Compositions and methods for recombinant protein production and, more particularly, fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related methods for recombinant protein production, are provided. | 2009-09-03 |
20090221033 | Polypeptides Having Lipase Activity And Polynucleotides Encoding Same - The invention provides polypeptides obtained by introducing mutations in one or more regions identified in a parent lipase. The polypeptides of the present invention have surprisingly been found to have a low specific activity towards short chain fatty acids leading to a reduced odor generation and an increased BR over the lipases known in the art. | 2009-09-03 |
20090221034 | Lipolytic Enzyme Variant With Improved Stability And Polynucleotides Encoding Same - The invention provides lipolytic enzyme variants having improved in-detergent stability and polynucleotides encoding same. Lipolytic enzyme variants with improved in-detergent stability are obtained by substituting certain specified amino acid residues in a parent lipolytic enzyme. | 2009-09-03 |
20090221035 | SYSTEMS AND METHODS FOR PROTEIN PRODUCTION - The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway. | 2009-09-03 |
20090221036 | RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY - Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life). | 2009-09-03 |
20090221037 | Fusion protein having the enhanced in vivo activity of erythropoietin - The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin. | 2009-09-03 |
20090221038 | Twin-Arginine Translocation (TAT) Streptomyces Signal Sequences - Described herein are novel Tat signal polypeptides and methods for using the Tat signal polypeptides for producing heterologous polypeptides. A novel reporter assay for testing the biological activity of the secreted proteins is also described. | 2009-09-03 |